Raceanisodamine eye drops for the treatment of childhood myopia

Objective To evaluate the efficacy and safety of 0.5% raceanisodamine eye drops for the treatment of childhood myopia.Methods Thirty cases of myopic children aged 5 to 12 years with a history of wearing glasses for more than half a year were randomly selected.Myopic children with structural ophthalmic diseases or those who had undergone other treatments for reducing the progression of myopia were excluded.Both eyes were treated with 0.5% raceanisodamine eye drops twice daily for more than half a year.Symptoms,routine ophthalmic tests,pupil size and reflex,intraocular pressure,cycloplegic refraction and axial length were collected at the first visit and follow-up visits.The patients were followed up every half year during the treatment period.A pairedsample t-test was used to compare the yearly progression of myopia,axial length,intraocular pressure and visual acuity before and after treatment.Results Twenty-two children completed the trial.The yearly progression of myopia before and after treatment was-1.02±0.48 diopters per year and-0.54±0.43 diopters per year,respectively,and after treatment progression was significantly slower than before treatment (P0.01).The corrected visual acuities before treatment and at the last visit were 4.92 ±0.11 and 4.98±0.07,respectively,and the corrected visual acuity at the last visit was significantly better than before treatment (P 0.01).The axial lengths before and after treatment were (24.75±1.65)mm and (25.27±1.76) mm,respectively,and axial length after treatment was significantly longer (P0.01).There were no complaints of photophobia or reduction in near vision,and there were no significant findings with tonometry,slit-lamp biomicroscopy or ophthalmoscopy.Conclusion 0.5% raceanisodamine eye drops were effective in slowing the progression of myopia.The drops are relatively safe and well tolerated.